Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Clin Cancer Res. 2022 Jul 1;28(13):2789–2795. doi: 10.1158/1078-0432.CCR-22-0162

Table 3.

Efficacy of sabizabulin at ≥ 63 mg daily (n = 55).

Parameter Result

Radiographic progresssion-free survival, months (n = 55)
 Median (95% CI) 11.4 (29.63–65.79)
ITT population, all patients with measurable disease at baseline (n = 29)
 Objective response rate CR 1/29, PR 5/29, CR+PR = 6/29 (20.7%)
PSA (n = 48) a
 Any PSA decline - evaluable patients 14/48 (29%)
 50% PSA decline 4/48 (8%)
a

Seven patients did not have baseline PSA levels and could not be evaluable for PSA declines.